Ajay Goel, Ph.D., AGAF, chair of the Department of Molecular Diagnostics and Experimental Therapeutics at the City of Hope speaks about the DDW 2021 abstract – A Liquid Biopsy Exosomal microRNA Panel For Predicting Recurrence Following Surgery In Patients With Pancreatic Ductal Adenocarcinoma.
Link to Article:
https://m.pharmasources.com/news/69994.html
The researchers looked at 210 plasma samples from pancreatic ductal adenocarcinoma patients, some of whom had neoadjuvant treatment (NAT) and others who did not. Small RNA sequencing was performed on 25 of the patients.
A 6-exosomal miRNA risk-prediction model was then optimized and trained by the researchers. The prediction model reliably distinguished patients with cancer recurrence (area under the curve [AUC] = 0.81, 95 percent confidence interval [CI], 0.70-0.89) and relapse-free survival (P) in the training cohort (n = 82 patients).
The miRNA panel performed similarly in an independent validation cohort of 57 patients in terms of relapse-free survival (P).
The model’s performance was similarly comparable among the 46 patients in the pos-NAT group in terms of cancer recurrence (AUC = 0.72; 95 percent CI, 0.57-0.85) and relapse-free survival (P = 0.01).